Home / Comparisons /
Solriamfetol vs pitolisant
This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.
Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026
Both were approved in 2019 for narcolepsy, and they are about as different from each other as two drugs for the same condition can be. Pitolisant treats cataplexy; solriamfetol does not. Pitolisant is not a controlled substance; solriamfetol is Schedule IV. They work through entirely different neurotransmitter systems. For a patient with narcolepsy type 1, where cataplexy is present, that first difference usually decides the question.
On this page
Comparison table
| Solriamfetol | Pitolisant | |
|---|---|---|
| Brand | Sunosi | Wakix |
| FDA approval | 2019 | 2019 |
| Mechanism | Dopamine and norepinephrine reuptake inhibitor | Histamine H3 antagonist and inverse agonist |
| Neurotransmitter system | Catecholamine | Histaminergic |
| Approved for | EDS in narcolepsy and OSA | Cataplexy or EDS in narcolepsy |
| Treats cataplexy | No | Yes |
| Paediatric indication | No | Yes |
| Scheduling | Schedule IV | Not scheduled |
| Half life | About 7 hours | Long, allowing once daily dosing |
| Cleared by | Kidneys | Liver |
| OSA indication | Yes | No |
Two different systems
Solriamfetol raises synaptic dopamine and norepinephrine by blocking their reuptake, the same broad approach as modafinil and the stimulants, executed more directly. Pitolisant works on histamine. H3 receptors sit on histamine neurons and act as autoreceptors, suppressing further histamine release when activated. Pitolisant blocks them and acts as an inverse agonist, removing that brake and increasing histamine release. Histamine is one of the brain’s principal wake promoting neurotransmitters, and histaminergic activity during the day is directly relevant in narcolepsy. Pitolisant is the only drug in this class that addresses wakefulness from that direction rather than through catecholamines.
Solriamfetol
blocks reuptake transporters
Synaptic dopamine and norepinephrine rise
signal persists longer
Increased wakefulness
Solriamfetol: reuptake blockade raises synaptic catecholamine levels directly.
Pitolisant
H3 antagonist and inverse agonist
Histamine autoreceptor blocked
release is no longer suppressed
More histamine released
a principal wake promoting transmitter
Increased wakefulness
Pitolisant: blocking the H3 autoreceptor removes the brake on histamine release.
Cataplexy
Cataplexy is sudden loss of muscle tone triggered by strong emotion, characteristic of narcolepsy type 1. Episodes last a few minutes at most and resolve on their own. Whether cataplexy is present is what distinguishes narcolepsy type 1 from type 2. Pitolisant is approved for cataplexy. Solriamfetol has no effect on it. Modafinil and armodafinil have no effect on it either.
For a patient with narcolepsy type 1 this is usually the deciding factor: a patient on solriamfetol who also has cataplexy needs a second agent to control it, most often sodium oxybate, whereas pitolisant may address both symptoms with one drug.
Controlled substance status
Solriamfetol is Schedule IV. Pitolisant is not scheduled at all, because it does not act on dopamine transporters and does not produce the reinforcing effects associated with stimulants. This is more than an administrative distinction: for patients with a history of substance use disorder, for patients uncomfortable taking a controlled substance long term, and in settings where controlled substance prescribing creates practical obstacles, pitolisant’s status is a genuine advantage.
Cardiac and interaction considerations
Cardiac conduction and antidepressants
Pitolisant affects cardiac conduction. There is a recognised concern about concurrent antidepressant use, where clinicians have noted possible facilitation of arrhythmias, though this has not been well studied, and practice on ECG monitoring varies between prescribers.
Solriamfetol, being minimally metabolised, has a relatively simple interaction profile; its main cautions are cardiovascular, given its effect on blood pressure and heart rate. Anyone taking an antidepressant should have either combination reviewed by the prescriber, but the pitolisant question is the more specific one.
Evidence
Solriamfetol’s phase 3 trial randomised 239 narcolepsy patients across three doses and placebo, with significant improvement on both the maintenance of wakefulness test and the Epworth Sleepiness Scale at week 12. Pitolisant was evaluated in two multicentre, randomised, double blind, placebo controlled studies in 261 patients with narcolepsy, with and without cataplexy; both demonstrated statistically significant improvement in Epworth Sleepiness Scale scores. There is no head to head trial between them.
Which a prescriber might choose
Pitolisant is the more likely choice where cataplexy is present, where the patient is paediatric, where controlled substance status is a concern, or where a history of substance use makes a scheduled drug undesirable. Solriamfetol is the more likely choice where the indication is obstructive sleep apnea rather than narcolepsy, where cardiac conduction or antidepressant interaction is a concern, or where a shorter acting agent is preferred.
Does solriamfetol treat cataplexy?
No. Solriamfetol has no effect on cataplexy. Pitolisant is approved for cataplexy in narcolepsy and can address both symptoms with one drug in patients with narcolepsy type 1.
Is pitolisant a controlled substance?
No. Pitolisant is not scheduled, because it does not act on dopamine transporters and does not produce the reinforcing effects associated with stimulants. Solriamfetol is Schedule IV.
Can pitolisant be used in children?
Yes, pitolisant has a paediatric indication for narcolepsy with cataplexy. Solriamfetol does not have a paediatric indication.
Is one more effective than the other?
There is no head to head trial. Both showed statistically significant improvement in Epworth Sleepiness Scale scores against placebo in their respective trials, but the choice between them usually depends on symptoms and other factors rather than a direct efficacy comparison.